EHA 2023 | COMMANDS: luspatercept vs epoetin alfa for anemia in ESA-naive LR-MDS

In this presentation, Matteo Della Porta, MD, Humanitas Research Hospital, Milan, Italy, discusses Phase III, open-label, randomized COMMANDS trial (NCT03682536) comparing luspatercept with epoetin alfa in ESA-naive transfusion-dependent lower risk (LR)-MDS patients. The primary endpoint was the proportion of patients who were RBC transfusion-independent (RBC-TI) ≥12 weeks with a concurrent mean hemoglobin increase ≥1.5 g/dL during weeks 1–24. The results showed that luspatercept demonstrated superiority over epoetin alfa with clinically meaningful improvements in RBC-TI and hematologic improvement-erythroid (HI-E) rates in ESA-naive LR-MDS patients who require transfusions. Luspatercept also showed more favorable outcomes compared to epoetin alfa across a spectrum of known MDS mutations. The safety profile of luspatercept was comparable with previous reports and no new safety events were identified. Luspatercept may transform the current landscape by establishing a new standard of treatment for ESA-naive patients with transfusion-dependent LR-MDS. This press briefing took place at the European Hematology Association (EHA) Congress 2023, held in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.